Target Information

Target General Information

Target ID

T98052 (Former ID: TTDI02305)

Target Name

SLAM family member 7 SLAMF7 (CS1)

Synonyms

UNQ576/PRO1138; SLAM family member 7; Protein 19A; Novel Ly9; Membrane protein FOAP-12; CRACC; CD319; CD2-like receptor-activating cytotoxic cells; CD2 subset 1

Click to Show/Hide

Gene Name

SLAMF7

Target Type

Successful target

[1]

Disease

[+] 1 Target-related Diseases

Multiple myeloma [ICD-11: 2A83]

Function

SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K. In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells. May play a role in lymphocyte adhesion. In LPS-activated monocytes negatively regulates production of proinflammatory cytokines. Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family.

Click to Show/Hide

BioChemical Class

Immunoglobulin

UniProt ID

SLAF7_HUMAN

Sequence

MAGSPTCLTLIYILWQLTGSAASGPVKELVGSVGGAVTFPLKSKVKQVDSIVWTFNTTPL
VTIQPEGGTIIVTQNRNRERVDFPDGGYSLKLSKLKKNDSGIYYVGIYSSSLQQPSTQEY
VLHVYEHLSKPKVTMGLQSNKNGTCVTNLTCCMEHGEEDVIYTWKALGQAANESHNGSIL
PISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAADDPDSSMVLLCLLLVPLLLSL
FVLGLFLWFLKRERQEEYIEEKKRVDICRETPNICPHSGENTEYDTIPHTNRTILKEDPA
NTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

AlphaFold

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 1 Approved Drugs

Elotuzumab

Drug Info

Approved

Multiple myeloma

[2], [3], [4]

Clinical Trial Drug(s)

[+] 6 Clinical Trial Drugs

PVX-410

Drug Info

Phase 2

Multiple myeloma

[4], [5], [6], [7]

ABBV-838

Drug Info

Phase 1

Multiple myeloma

[4]

BCMA-CS1 cCAR

Drug Info

Phase 1

Multiple myeloma

[8]

CS1-CAR T Therapy

Drug Info

Phase 1

Plasma cell myeloma

[9]

MB-104

Drug Info

Phase 1

Multiple myeloma

[10]

UCARTCS1

Drug Info

Phase 1

Multiple myeloma

[11]

Mode of Action

[+] 3 Modes of Action

Modulator

[+] 1 Modulator drugs

PVX-410

Drug Info

[1], [12]

Inhibitor

[+] 1 Inhibitor drugs

ABBV-838

Drug Info

[4]

CAR-T-Cell-Therapy

[+] 1 CAR-T-Cell-Therapy drugs

CS1-CAR T Therapy

Drug Info

[9]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Similarity Proteins

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Similarity Proteins

Protein Name	Pfam ID	Percentage of Identity (%)	E value
SLAM family member 7 SLAMF7 (CS1)		100.000 (335/335)	0.00E+00
SLAM family member 5 (CD84)		31.034 (108/348)	7.38E-35
T-lymphocyte surface antigen Ly-9 (LY9)		32.365 (78/241)	6.53E-29
SLAM family member 9 (SLAMF9)		33.333 (67/201)	1.24E-28
SLAM family member 6 (SLAMF6)	PF07686	29.193 (94/322)	4.16E-25
Signaling lymphocytic activation molecule (SLAMF1)	PF06214	24.427 (64/262)	4.67E-09
SLAM family member 8 (SLAMF8)		28.682 (37/129)	1.34E-06
Hepatocyte cell adhesion molecule (HEPACAM)	PF13927 ; PF07686	26.108 (53/203)	1.33E-05
Natural killer cell receptor 2B4 (CD244)	PF13895 ; PF11465	21.739 (70/322)	6.06E-05
T-cell surface antigen CD2 (CD2)	PF05790 ; PF07686	25.989 (46/177)	2.56E-04
Biliary glycoprotein 1 (CEACAM1)	PF00047 ; PF13895 ; PF13927 ; PF07686 More >>	27.152 (41/151)	2.00E-03
Click to Show/Hide the Information of Human Similarity Proteins

Target Profiles in Patients

Top

Target Expression
Profile (TEP)

Target Expression Profile Info

References

Top

REF 1

Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.

REF 2

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8361).

REF 3

ClinicalTrials.gov (NCT01335399) Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma. U.S. National Institutesof Health.

REF 4

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 5

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 6

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 7

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 8

ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 9

ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

REF 10

ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma. U.S. National Institutes of Health.

REF 11

ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.

REF 12

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep;8(9):2616-24.

REF 13

Clinical pipeline report, company report or official report of Mustang Bio.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN